Analysis of Solvency Ratios
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
IQVIA Holdings Inc., solvency ratios
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | IQVIA Holdings Inc. debt to equity ratio improved from 2020 to 2021 but then deteriorated significantly from 2021 to 2022. |
| Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | IQVIA Holdings Inc. debt to equity ratio (including operating lease liability) improved from 2020 to 2021 but then deteriorated significantly from 2021 to 2022. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | IQVIA Holdings Inc. debt to capital ratio improved from 2020 to 2021 but then deteriorated significantly from 2021 to 2022. |
| Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | IQVIA Holdings Inc. debt to capital ratio (including operating lease liability) improved from 2020 to 2021 but then deteriorated significantly from 2021 to 2022. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | IQVIA Holdings Inc. debt to assets ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
| Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | IQVIA Holdings Inc. debt to assets ratio (including operating lease liability) improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | IQVIA Holdings Inc. financial leverage ratio decreased from 2020 to 2021 but then increased from 2021 to 2022 exceeding 2020 level. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | IQVIA Holdings Inc. interest coverage ratio improved from 2020 to 2021 and from 2021 to 2022. |
| Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | IQVIA Holdings Inc. fixed charge coverage ratio improved from 2020 to 2021 and from 2021 to 2022. |
Debt to Equity
IQVIA Holdings Inc., debt to equity calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | 152) | 91) | 149) | 100) | 100) | |
| Current finance lease liabilities | 5) | 9) | —) | —) | —) | |
| Long-term debt, less current portion | 12,595) | 12,034) | 12,384) | 11,545) | 10,907) | |
| Long-term finance lease liabilities | 224) | 177) | 122) | —) | —) | |
| Total debt | 12,976) | 12,311) | 12,655) | 11,645) | 11,007) | |
| Equity attributable to IQVIA Holdings Inc.’s stockholders | 5,765) | 6,042) | 6,001) | 6,003) | 6,714) | |
| Solvency Ratio | ||||||
| Debt to equity1 | 2.25 | 2.04 | 2.11 | 1.94 | 1.64 | |
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| AbbVie Inc. | 3.67 | 4.98 | 6.58 | — | — | |
| Amgen Inc. | 10.64 | 4.97 | 3.51 | 3.09 | — | |
| Bristol-Myers Squibb Co. | 1.27 | 1.24 | 1.34 | 0.91 | — | |
| Danaher Corp. | 0.39 | 0.49 | 0.53 | 0.72 | — | |
| Eli Lilly & Co. | 1.52 | 1.88 | 2.94 | 5.88 | — | |
| Gilead Sciences Inc. | 1.19 | 1.27 | 1.73 | 1.09 | — | |
| Johnson & Johnson | 0.52 | 0.46 | 0.56 | 0.47 | — | |
| Merck & Co. Inc. | 0.67 | 0.87 | 1.26 | 1.02 | — | |
| Pfizer Inc. | 0.37 | 0.50 | 0.63 | 0.83 | — | |
| Regeneron Pharmaceuticals Inc. | 0.12 | 0.14 | 0.24 | 0.06 | — | |
| Thermo Fisher Scientific Inc. | 0.78 | 0.85 | 0.63 | 0.60 | — | |
| Debt to Equity, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.83 | 0.95 | 1.15 | 1.11 | — | |
| Debt to Equity, Industry | ||||||
| Health Care | 0.74 | 0.80 | 0.90 | 0.91 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Debt to equity = Total debt ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 12,976 ÷ 5,765 = 2.25
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | IQVIA Holdings Inc. debt to equity ratio improved from 2020 to 2021 but then deteriorated significantly from 2021 to 2022. |
Debt to Equity (including Operating Lease Liability)
IQVIA Holdings Inc., debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | 152) | 91) | 149) | 100) | 100) | |
| Current finance lease liabilities | 5) | 9) | —) | —) | —) | |
| Long-term debt, less current portion | 12,595) | 12,034) | 12,384) | 11,545) | 10,907) | |
| Long-term finance lease liabilities | 224) | 177) | 122) | —) | —) | |
| Total debt | 12,976) | 12,311) | 12,655) | 11,645) | 11,007) | |
| Current operating lease liabilities (included in Other current liabilities) | 111) | 140) | 156) | 153) | —) | |
| Long-term operating lease liabilities | 264) | 313) | 371) | 396) | —) | |
| Total debt (including operating lease liability) | 13,351) | 12,764) | 13,182) | 12,194) | 11,007) | |
| Equity attributable to IQVIA Holdings Inc.’s stockholders | 5,765) | 6,042) | 6,001) | 6,003) | 6,714) | |
| Solvency Ratio | ||||||
| Debt to equity (including operating lease liability)1 | 2.32 | 2.11 | 2.20 | 2.03 | 1.64 | |
| Benchmarks | ||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | 3.72 | 5.03 | 6.66 | — | — | |
| Amgen Inc. | 10.83 | 5.07 | 3.55 | 3.15 | — | |
| Bristol-Myers Squibb Co. | 1.31 | 1.27 | 1.37 | 0.92 | — | |
| Danaher Corp. | 0.41 | 0.52 | 0.56 | 0.74 | — | |
| Eli Lilly & Co. | 1.59 | 1.96 | 3.06 | 6.11 | — | |
| Gilead Sciences Inc. | 1.22 | 1.30 | 1.76 | 1.12 | — | |
| Johnson & Johnson | 0.53 | 0.47 | 0.57 | 0.48 | — | |
| Merck & Co. Inc. | 0.70 | 0.91 | 1.32 | 1.06 | — | |
| Pfizer Inc. | 0.41 | 0.54 | 0.65 | 0.85 | — | |
| Regeneron Pharmaceuticals Inc. | 0.12 | 0.15 | 0.25 | 0.07 | — | |
| Thermo Fisher Scientific Inc. | 0.82 | 0.89 | 0.65 | 0.62 | — | |
| Debt to Equity (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.86 | 0.98 | 1.18 | 1.13 | — | |
| Debt to Equity (including Operating Lease Liability), Industry | ||||||
| Health Care | 0.79 | 0.85 | 0.96 | 0.97 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 13,351 ÷ 5,765 = 2.32
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | IQVIA Holdings Inc. debt to equity ratio (including operating lease liability) improved from 2020 to 2021 but then deteriorated significantly from 2021 to 2022. |
Debt to Capital
IQVIA Holdings Inc., debt to capital calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | 152) | 91) | 149) | 100) | 100) | |
| Current finance lease liabilities | 5) | 9) | —) | —) | —) | |
| Long-term debt, less current portion | 12,595) | 12,034) | 12,384) | 11,545) | 10,907) | |
| Long-term finance lease liabilities | 224) | 177) | 122) | —) | —) | |
| Total debt | 12,976) | 12,311) | 12,655) | 11,645) | 11,007) | |
| Equity attributable to IQVIA Holdings Inc.’s stockholders | 5,765) | 6,042) | 6,001) | 6,003) | 6,714) | |
| Total capital | 18,741) | 18,353) | 18,656) | 17,648) | 17,721) | |
| Solvency Ratio | ||||||
| Debt to capital1 | 0.69 | 0.67 | 0.68 | 0.66 | 0.62 | |
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| AbbVie Inc. | 0.79 | 0.83 | 0.87 | 1.14 | — | |
| Amgen Inc. | 0.91 | 0.83 | 0.78 | 0.76 | — | |
| Bristol-Myers Squibb Co. | 0.56 | 0.55 | 0.57 | 0.48 | — | |
| Danaher Corp. | 0.28 | 0.33 | 0.35 | 0.42 | — | |
| Eli Lilly & Co. | 0.60 | 0.65 | 0.75 | 0.85 | — | |
| Gilead Sciences Inc. | 0.54 | 0.56 | 0.63 | 0.52 | — | |
| Johnson & Johnson | 0.34 | 0.31 | 0.36 | 0.32 | — | |
| Merck & Co. Inc. | 0.40 | 0.46 | 0.56 | 0.50 | — | |
| Pfizer Inc. | 0.27 | 0.33 | 0.39 | 0.45 | — | |
| Regeneron Pharmaceuticals Inc. | 0.11 | 0.13 | 0.20 | 0.06 | — | |
| Thermo Fisher Scientific Inc. | 0.44 | 0.46 | 0.39 | 0.37 | — | |
| Debt to Capital, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.45 | 0.49 | 0.54 | 0.53 | — | |
| Debt to Capital, Industry | ||||||
| Health Care | 0.42 | 0.44 | 0.47 | 0.48 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Debt to capital = Total debt ÷ Total capital
= 12,976 ÷ 18,741 = 0.69
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | IQVIA Holdings Inc. debt to capital ratio improved from 2020 to 2021 but then deteriorated significantly from 2021 to 2022. |
Debt to Capital (including Operating Lease Liability)
IQVIA Holdings Inc., debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | 152) | 91) | 149) | 100) | 100) | |
| Current finance lease liabilities | 5) | 9) | —) | —) | —) | |
| Long-term debt, less current portion | 12,595) | 12,034) | 12,384) | 11,545) | 10,907) | |
| Long-term finance lease liabilities | 224) | 177) | 122) | —) | —) | |
| Total debt | 12,976) | 12,311) | 12,655) | 11,645) | 11,007) | |
| Current operating lease liabilities (included in Other current liabilities) | 111) | 140) | 156) | 153) | —) | |
| Long-term operating lease liabilities | 264) | 313) | 371) | 396) | —) | |
| Total debt (including operating lease liability) | 13,351) | 12,764) | 13,182) | 12,194) | 11,007) | |
| Equity attributable to IQVIA Holdings Inc.’s stockholders | 5,765) | 6,042) | 6,001) | 6,003) | 6,714) | |
| Total capital (including operating lease liability) | 19,116) | 18,806) | 19,183) | 18,197) | 17,721) | |
| Solvency Ratio | ||||||
| Debt to capital (including operating lease liability)1 | 0.70 | 0.68 | 0.69 | 0.67 | 0.62 | |
| Benchmarks | ||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | 0.79 | 0.83 | 0.87 | 1.14 | — | |
| Amgen Inc. | 0.92 | 0.84 | 0.78 | 0.76 | — | |
| Bristol-Myers Squibb Co. | 0.57 | 0.56 | 0.58 | 0.48 | — | |
| Danaher Corp. | 0.29 | 0.34 | 0.36 | 0.43 | — | |
| Eli Lilly & Co. | 0.61 | 0.66 | 0.75 | 0.86 | — | |
| Gilead Sciences Inc. | 0.55 | 0.56 | 0.64 | 0.53 | — | |
| Johnson & Johnson | 0.35 | 0.32 | 0.36 | 0.33 | — | |
| Merck & Co. Inc. | 0.41 | 0.48 | 0.57 | 0.51 | — | |
| Pfizer Inc. | 0.29 | 0.35 | 0.39 | 0.46 | — | |
| Regeneron Pharmaceuticals Inc. | 0.11 | 0.13 | 0.20 | 0.07 | — | |
| Thermo Fisher Scientific Inc. | 0.45 | 0.47 | 0.40 | 0.38 | — | |
| Debt to Capital (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.46 | 0.50 | 0.54 | 0.53 | — | |
| Debt to Capital (including Operating Lease Liability), Industry | ||||||
| Health Care | 0.44 | 0.46 | 0.49 | 0.49 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 13,351 ÷ 19,116 = 0.70
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | IQVIA Holdings Inc. debt to capital ratio (including operating lease liability) improved from 2020 to 2021 but then deteriorated significantly from 2021 to 2022. |
Debt to Assets
IQVIA Holdings Inc., debt to assets calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | 152) | 91) | 149) | 100) | 100) | |
| Current finance lease liabilities | 5) | 9) | —) | —) | —) | |
| Long-term debt, less current portion | 12,595) | 12,034) | 12,384) | 11,545) | 10,907) | |
| Long-term finance lease liabilities | 224) | 177) | 122) | —) | —) | |
| Total debt | 12,976) | 12,311) | 12,655) | 11,645) | 11,007) | |
| Total assets | 25,337) | 24,689) | 24,564) | 23,251) | 22,549) | |
| Solvency Ratio | ||||||
| Debt to assets1 | 0.51 | 0.50 | 0.52 | 0.50 | 0.49 | |
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| AbbVie Inc. | 0.46 | 0.52 | 0.57 | 0.75 | — | |
| Amgen Inc. | 0.60 | 0.54 | 0.52 | 0.50 | — | |
| Bristol-Myers Squibb Co. | 0.41 | 0.41 | 0.43 | 0.36 | — | |
| Danaher Corp. | 0.23 | 0.27 | 0.28 | 0.35 | — | |
| Eli Lilly & Co. | 0.33 | 0.35 | 0.36 | 0.39 | — | |
| Gilead Sciences Inc. | 0.40 | 0.39 | 0.46 | 0.40 | — | |
| Johnson & Johnson | 0.21 | 0.19 | 0.20 | 0.18 | — | |
| Merck & Co. Inc. | 0.28 | 0.31 | 0.35 | 0.31 | — | |
| Pfizer Inc. | 0.18 | 0.21 | 0.26 | 0.31 | — | |
| Regeneron Pharmaceuticals Inc. | 0.09 | 0.11 | 0.16 | 0.05 | — | |
| Thermo Fisher Scientific Inc. | 0.35 | 0.37 | 0.31 | 0.30 | — | |
| Debt to Assets, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.31 | 0.33 | 0.36 | 0.36 | — | |
| Debt to Assets, Industry | ||||||
| Health Care | 0.27 | 0.29 | 0.30 | 0.31 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Debt to assets = Total debt ÷ Total assets
= 12,976 ÷ 25,337 = 0.51
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | IQVIA Holdings Inc. debt to assets ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
Debt to Assets (including Operating Lease Liability)
IQVIA Holdings Inc., debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | 152) | 91) | 149) | 100) | 100) | |
| Current finance lease liabilities | 5) | 9) | —) | —) | —) | |
| Long-term debt, less current portion | 12,595) | 12,034) | 12,384) | 11,545) | 10,907) | |
| Long-term finance lease liabilities | 224) | 177) | 122) | —) | —) | |
| Total debt | 12,976) | 12,311) | 12,655) | 11,645) | 11,007) | |
| Current operating lease liabilities (included in Other current liabilities) | 111) | 140) | 156) | 153) | —) | |
| Long-term operating lease liabilities | 264) | 313) | 371) | 396) | —) | |
| Total debt (including operating lease liability) | 13,351) | 12,764) | 13,182) | 12,194) | 11,007) | |
| Total assets | 25,337) | 24,689) | 24,564) | 23,251) | 22,549) | |
| Solvency Ratio | ||||||
| Debt to assets (including operating lease liability)1 | 0.53 | 0.52 | 0.54 | 0.52 | 0.49 | |
| Benchmarks | ||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | 0.46 | 0.53 | 0.58 | 0.75 | — | |
| Amgen Inc. | 0.61 | 0.56 | 0.53 | 0.51 | — | |
| Bristol-Myers Squibb Co. | 0.42 | 0.42 | 0.44 | 0.37 | — | |
| Danaher Corp. | 0.25 | 0.28 | 0.29 | 0.36 | — | |
| Eli Lilly & Co. | 0.34 | 0.36 | 0.37 | 0.41 | — | |
| Gilead Sciences Inc. | 0.41 | 0.40 | 0.47 | 0.41 | — | |
| Johnson & Johnson | 0.22 | 0.19 | 0.21 | 0.18 | — | |
| Merck & Co. Inc. | 0.29 | 0.33 | 0.37 | 0.32 | — | |
| Pfizer Inc. | 0.20 | 0.23 | 0.27 | 0.32 | — | |
| Regeneron Pharmaceuticals Inc. | 0.09 | 0.11 | 0.16 | 0.05 | — | |
| Thermo Fisher Scientific Inc. | 0.37 | 0.38 | 0.33 | 0.32 | — | |
| Debt to Assets (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.32 | 0.34 | 0.37 | 0.37 | — | |
| Debt to Assets (including Operating Lease Liability), Industry | ||||||
| Health Care | 0.29 | 0.31 | 0.33 | 0.33 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 13,351 ÷ 25,337 = 0.53
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | IQVIA Holdings Inc. debt to assets ratio (including operating lease liability) improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
Financial Leverage
IQVIA Holdings Inc., financial leverage calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Total assets | 25,337) | 24,689) | 24,564) | 23,251) | 22,549) | |
| Equity attributable to IQVIA Holdings Inc.’s stockholders | 5,765) | 6,042) | 6,001) | 6,003) | 6,714) | |
| Solvency Ratio | ||||||
| Financial leverage1 | 4.39 | 4.09 | 4.09 | 3.87 | 3.36 | |
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| AbbVie Inc. | 8.04 | 9.51 | 11.51 | — | — | |
| Amgen Inc. | 17.79 | 9.13 | 6.69 | 6.17 | — | |
| Bristol-Myers Squibb Co. | 3.12 | 3.04 | 3.13 | 2.52 | — | |
| Danaher Corp. | 1.68 | 1.84 | 1.92 | 2.05 | — | |
| Eli Lilly & Co. | 4.65 | 5.44 | 8.27 | 15.07 | — | |
| Gilead Sciences Inc. | 2.97 | 3.23 | 3.76 | 2.74 | — | |
| Johnson & Johnson | 2.44 | 2.46 | 2.76 | 2.65 | — | |
| Merck & Co. Inc. | 2.37 | 2.77 | 3.62 | 3.26 | — | |
| Pfizer Inc. | 2.06 | 2.35 | 2.44 | 2.65 | — | |
| Regeneron Pharmaceuticals Inc. | 1.29 | 1.36 | 1.56 | 1.34 | — | |
| Thermo Fisher Scientific Inc. | 2.21 | 2.33 | 2.00 | 1.97 | — | |
| Financial Leverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 2.67 | 2.90 | 3.21 | 3.10 | — | |
| Financial Leverage, Industry | ||||||
| Health Care | 2.69 | 2.79 | 2.95 | 2.93 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Financial leverage = Total assets ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 25,337 ÷ 5,765 = 4.39
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | IQVIA Holdings Inc. financial leverage ratio decreased from 2020 to 2021 but then increased from 2021 to 2022 exceeding 2020 level. |
Interest Coverage
IQVIA Holdings Inc., interest coverage calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to IQVIA Holdings Inc. | 1,091) | 966) | 279) | 191) | 259) | |
| Add: Net income attributable to noncontrolling interest | —) | 5) | 29) | 36) | 25) | |
| Add: Income tax expense | 260) | 163) | 72) | 116) | 59) | |
| Add: Interest expense | 416) | 375) | 416) | 447) | 414) | |
| Earnings before interest and tax (EBIT) | 1,767) | 1,509) | 796) | 790) | 757) | |
| Solvency Ratio | ||||||
| Interest coverage1 | 4.25 | 4.02 | 1.91 | 1.77 | 1.83 | |
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| AbbVie Inc. | 7.04 | 6.36 | 2.38 | 5.72 | — | |
| Amgen Inc. | 6.22 | 6.60 | 7.44 | 8.09 | — | |
| Bristol-Myers Squibb Co. | 7.26 | 7.07 | -3.84 | 8.58 | — | |
| Danaher Corp. | 40.30 | 32.92 | 17.35 | 31.44 | — | |
| Eli Lilly & Co. | 21.53 | 19.12 | 21.11 | 14.15 | — | |
| Gilead Sciences Inc. | 7.22 | 9.27 | 2.70 | 6.19 | — | |
| Johnson & Johnson | 79.71 | 125.46 | 83.07 | 55.49 | — | |
| Merck & Co. Inc. | 18.09 | 18.22 | 11.58 | 13.84 | — | |
| Pfizer Inc. | 29.05 | 19.83 | 6.17 | 12.23 | — | |
| Regeneron Pharmaceuticals Inc. | 82.80 | 163.75 | 67.97 | 81.43 | — | |
| Thermo Fisher Scientific Inc. | 11.56 | 17.49 | 14.07 | 7.02 | — | |
| Interest Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 15.04 | 14.71 | 7.28 | 11.23 | — | |
| Interest Coverage, Industry | ||||||
| Health Care | 12.44 | 12.11 | 7.72 | 8.87 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Interest coverage = EBIT ÷ Interest expense
= 1,767 ÷ 416 = 4.25
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | IQVIA Holdings Inc. interest coverage ratio improved from 2020 to 2021 and from 2021 to 2022. |
Fixed Charge Coverage
IQVIA Holdings Inc., fixed charge coverage calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to IQVIA Holdings Inc. | 1,091) | 966) | 279) | 191) | 259) | |
| Add: Net income attributable to noncontrolling interest | —) | 5) | 29) | 36) | 25) | |
| Add: Income tax expense | 260) | 163) | 72) | 116) | 59) | |
| Add: Interest expense | 416) | 375) | 416) | 447) | 414) | |
| Earnings before interest and tax (EBIT) | 1,767) | 1,509) | 796) | 790) | 757) | |
| Add: Operating lease cost | 171) | 184) | 209) | 193) | 197) | |
| Earnings before fixed charges and tax | 1,938) | 1,693) | 1,005) | 983) | 954) | |
| Interest expense | 416) | 375) | 416) | 447) | 414) | |
| Operating lease cost | 171) | 184) | 209) | 193) | 197) | |
| Fixed charges | 587) | 559) | 625) | 640) | 611) | |
| Solvency Ratio | ||||||
| Fixed charge coverage1 | 3.30 | 3.03 | 1.61 | 1.54 | 1.56 | |
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| AbbVie Inc. | 6.54 | 5.90 | 2.28 | 5.42 | — | |
| Amgen Inc. | 5.52 | 5.67 | 6.48 | 7.12 | — | |
| Bristol-Myers Squibb Co. | 6.30 | 6.01 | -3.08 | 7.10 | — | |
| Danaher Corp. | 13.41 | 10.85 | 7.10 | 8.38 | — | |
| Eli Lilly & Co. | 15.17 | 13.33 | 15.06 | 10.18 | — | |
| Gilead Sciences Inc. | 6.30 | 8.15 | 2.45 | 5.46 | — | |
| Johnson & Johnson | 38.72 | 48.16 | 33.93 | 28.72 | — | |
| Merck & Co. Inc. | 13.69 | 13.08 | 8.47 | 10.31 | — | |
| Pfizer Inc. | 18.79 | 14.22 | 4.98 | 9.88 | — | |
| Regeneron Pharmaceuticals Inc. | 68.67 | 138.96 | 57.70 | 60.98 | — | |
| Thermo Fisher Scientific Inc. | 8.12 | 12.19 | 10.30 | 5.61 | — | |
| Fixed Charge Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 11.59 | 11.35 | 5.90 | 8.99 | — | |
| Fixed Charge Coverage, Industry | ||||||
| Health Care | 8.84 | 8.58 | 5.70 | 6.61 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= 1,938 ÷ 587 = 3.30
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | IQVIA Holdings Inc. fixed charge coverage ratio improved from 2020 to 2021 and from 2021 to 2022. |